Dynavax Technologies | Spese Di Vendita E Di Amministrazione



Selling And Administration Expenses Cambiamento Data
AbbVie USD 3.86B 306M 2024-12
Adma Biologics USD 24.59M 5.01M 2024-12
Amgen USD 1.88B 253M 2024-12
AstraZeneca USD 5.55B 307M 2024-12
Biogen USD 677.3M 99.6M 2024-12
BioMarin Pharmaceutical USD 256.77M 46.81M 2024-12
Bristol-Myers Squibb USD 2.1B 129M 2024-12
Dynavax Technologies USD 41.58M 1.48M 2024-12
Gilead Sciences USD 1.86B 451M 2024-12
Glaxosmithkline GBP 2.7B 632M 2024-12
Merck USD 2.85B 148M 2024-12
Neurocrine Biosciences USD 287.8M 53.5M 2024-12
Novartis USD 3.5B 368M 2024-12
Pfizer USD 4.27B 1.06B 2024-12
Regeneron Pharmaceuticals USD 792.2M 77.8M 2024-12
Roche Holding CHF 3.61B 381M 2024-12
Sarepta Therapeutics USD 163.87M 35.67M 2024-12
TG Therapeutics USD 38.96M 3M 2024-12
Vertex Pharmaceuticals USD 377.6M 5.8M 2024-12



Dynavax Technologies Spese Di Vendita E Di Amministrazione - Valori correnti, dati storici, previsioni, statistiche, grafici e calendario economico - Mar 2025.